On Wednesday, Vor Bio Inc. (NASDAQ:VOR) announced that its collaborator, RemeGen Co., Ltd., achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in ...
Vor Biopharma Inc (NASDAQ:VOR) saw its stock climb 2.9% following news that its partner RemeGen Co., Ltd (USOTC:REGMY) successfully hit the primary endpoint in Stage A of a Phase 3 trial for ...
New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback